Your baby's life story begins

The life-saving science behind RhoGAM

RhoGAM Ultra-Filtered PLUS [Rho(D) Immune Globulin (Human)] is a prescription medicine given by intramuscular injection that is used to prevent Rh immunization, a condition in which an individual with Rh-negative blood develops antibodies after exposure to Rh-positive blood.

When should RhoGAM be used?

Routine Rh sensitization prevention

If the father or baby is not conclusively shown to be Rh-negative, RhoGAM should be given to an Rh-negative mother in these situations to prevent Rh sensitization:

  • At 26 to 28 weeks of pregnancy
  • After delivery of an Rh-positive baby

Other times of prevention

  • Maternal or fetal bleeding during pregnancy from certain conditions
  • Actual or threatened pregnancy loss at any stage
  • Ectopic pregnancy (pregnancy in which the fertilized egg implants outside the uterus)
  • Amniocentesis
  • Chorionic villus sampling (CVS)
  • Manipulative procedures (such as for a breech presentation)
  • Other obstetrical trauma

Ask your healthcare professional when RhoGAM is right for you

How RhoGAM works

RhoGAM helps prevent the production of antibodies (Rh sensitization). Rh sensitization of the Rh-negative mother during pregnancy can lead to hemolytic disease of the fetus and newborn (HDFN) in future pregnancies.

How HDFN Develops

Sometimes a baby's Rh-positive red blood cells enter the Rh-negative mother's bloodstream

The mother produces antibodies against the baby's red blood cells. Usually, these antibodies do not affect her first baby, but future Rh-positive babies are at risk

If the second baby is Rh-positive, the mother's antibodies will destroy the baby's red blood cells, putting the baby at risk for HDFN

How RhoGAM works

RhoGAM prevents the Rh-negative expectant mother from making antibodies during pregnancy that could cause HDFN in future pregnancies

As long as the Rh-negative mother receives RhoGAM appropriately during every pregnancy, her babies are at very low risk of developing HDFN

Why ask for RhoGAM? It provides protection as early as 26 weeks.1

Studies have found that the most effective way to reduce Rh sensitization is to receive anti-D therapy at 28 weeks of pregnancy.2-4

RhoGAM has the longest half-life of other anti-D products.5

Half-life is an indicator of how long RhoGAM circulates in your system.6

RhoGAM's half-life aligns with the American College of Obstetricians and Gynecologists (ACOG) guidelines.1,7

RhoGAM helped set the standards and clinical practice guidelines that are still followed today.

RhoGAM has remained a reliable choice for 5 decades as the first anti-D product available.8

Talk to your doctor to learn about how RhoGAM may help protect you and your baby during your pregnancy.

Receiving RhoGAM

In most cases, you will receive a dose of RhoGAM between 26-28 weeks of pregnancy.

During pregnancy, the baby's Rh blood type can only be determined through invasive procedures. Since the Rh-positive blood type is much more common than Rh-negative, most physicians will administer RhoGAM without determining the blood type of the baby during pregnancy.

If your baby is found to be Rh-positive at birth, you will receive a second dose of RhoGAM within 72 hours after delivery.*

If your baby is determined to be Rh-negative at birth, you do not need an additional dose of RhoGAM.

RhoGAM is an injection available by prescription only that will be given by your healthcare professional. Please note, RhoGAM is intended for maternal administration only and should not be injected into the newborn infant. While there can be mixing of blood between mom and baby, the dose of antibodies in RhoGAM given to Rh-negative moms has never been shown to harm the fetus. Millions of doses of RhoGAM have been administered safely to Rh-negative mothers without affecting their babies.

At any time during your pregnancy, be sure to notify your healthcare provider immediately if you have vaginal bleeding or experience any abdominal trauma. You may need an additional dose of RhoGAM.

*Your doctor will determine the appropriate dose of RhoGAM after delivery.

KEDRION Biopharma takes great pride in our excellent safety and quality record

Plasma Safety and COVID

COVID-19 is a highly contagious infection spread by respiratory droplets. It is caused by SARS-CoV-2, a single strand enveloped RNA virus.9

RhoGAM is purified from human plasma containing anti-Rh, or anti-D.

RhoGAM's patented Viresolve 180 process inactivates enveloped viruses, or those covered with a "fatty" outer coat similar to COVID-19.1

Our donors play an important role in the RhoGAM story

The story of RhoGAM involves a history of generosity from our blood donors with Rh antibodies. Today, plasma for RhoGAM is sourced from a single donor center owned and operated by KEDPLASMA, LLC. All donors are carefully screened and tested for blood-borne pathogens.

RhoGAM is made from human plasma. Products made from human blood may carry a risk of transmitting infectious agents (e.g., viruses, the variant Creutzfeldt-Jakob disease [vCJD] and, theoretically, the Creutzfeldt-Jakob disease [CJD] agent).